Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations
about
Molecular physiology of mammalian glucokinaseHomotropic allosteric regulation in monomeric mammalian glucokinaseThe hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic ratsCrystal structure of E339K mutated human glucokinase reveals changes in the ATP binding siteInsights into Mechanism of Glucokinase ActivationA panel of diverse assays to interrogate the interaction between glucokinase and glucokinase regulatory protein, two vital proteins in human diseaseSpecificity in beta cell expression of L-3-hydroxyacyl-CoA dehydrogenase, short chain, and potential role in down-regulating insulin releaseSmall molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humansAn allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolismPhosphatase-coupled universal kinase assay and kinetics for first-order-rate coupling reactionInvestigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?Clinical and molecular data from 61 Brazilian cases of Congenital Hyperinsulinemic Hypoglycemia.ATP-sensitive potassium channelopathies: focus on insulin secretionInheritance of rare functional GCKR variants and their contribution to triglyceride levels in families.Thermal stability of glucokinase (GK) as influenced by the substrate glucose, an allosteric glucokinase activator drug (GKA) and the osmolytes glycerol and ureaOrder-disorder transitions govern kinetic cooperativity and allostery of monomeric human glucokinaseBiochemical basis of glucokinase activation and the regulation by glucokinase regulatory protein in naturally occurring mutations.Glucagon-like peptide 1 stimulates post-translational activation of glucokinase in pancreatic beta cells.Discovery of a novel site regulating glucokinase activity following characterization of a new mutation causing hyperinsulinemic hypoglycemia in humansCharacterization of a novel glucokinase activator in rat and mouse modelsRepair of diverse diabetic defects of β-cells in man and mouse by pharmacological glucokinase activationDual allosteric activation mechanisms in monomeric human glucokinase.Association with nitric oxide synthase on insulin secretory granules regulates glucokinase protein levels.Type 2 Diabetes Genetics: Beyond GWAS.Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction.Genetic polymorphism of glucokinase on the risk of type 2 diabetes and impaired glucose regulation: evidence based on 298,468 subjects.S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice.Glucokinase activators in diabetes management.Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glucokinase activating mutations.Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism.Glucokinase activators.Molecular targeting of the GK-GKRP pathway in diabetes.An Egyptian case of congenital hyperinsulinism of infancy due to a novel mutation in KCNJ11 encoding Kir6.2 and response to octreotide.Congenital hyperinsulinism caused by hexokinase I expression or glucokinase-activating mutation in a subset of β-cells.Structure-function analysis of the alpha5 and the alpha13 helices of human glucokinase: description of two novel activating mutations.Role of connecting loop I in catalysis and allosteric regulation of human glucokinase.A new compound heterozygosis for inactivating mutations in the glucokinase gene as cause of permanent neonatal diabetes mellitus (PNDM) in double-first cousins.The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver.Glucokinase thermolability and hepatic regulatory protein binding are essential factors for predicting the blood glucose phenotype of missense mutations.Insights into the structure and regulation of glucokinase from a novel mutation (V62M), which causes maturity-onset diabetes of the young.
P2860
Q24653018-B8506204-C04F-485E-BA18-5A086F035F5AQ26852900-16C7EC46-7A7E-4F45-B575-40E586E591FBQ27333171-9DB9F173-7ED6-4F0B-A782-3ED4B207BD2CQ27667057-44C6BF59-BDF1-4B25-8AA2-54C2161D40CAQ27677010-BF25045A-25C4-4903-8B09-5C9D756AEEBEQ28539913-519F7094-BFB5-44FB-AFD9-B455E1447B73Q28566284-E91B127C-2849-4339-99AC-F12EBB6E97E2Q28576077-FC55A4C2-DDD1-4BA9-A622-B6DA9F5F6C8EQ28583616-10F77AF4-DA4E-4147-ABF1-1B92A5A5D684Q28741504-41DD9566-6237-4A59-B3EF-F2D9D4A70E93Q30426407-8B85AFAC-CE2D-4ECD-B56E-342D16C597B3Q30951393-8BC4CBF9-CDCF-440A-B155-568E25EDE870Q33905803-D9E1D4C0-271F-4834-854A-697E1A2CD2E0Q34211860-4E367770-1D11-41F9-9A57-43BE1C5BB8BDQ34269126-09F000F2-E7E9-427F-BBA3-5084DBACCD53Q34524540-A1599317-D621-4C7E-9C7F-BB79A05E81C0Q34578853-EAF3379E-D4E7-4681-A13A-DE2AFCB0DE2EQ34947569-CE9192F7-267C-4F01-BC8E-BCE19D931A8FQ34998302-2C7C40F4-1CE4-478F-9C06-7B583AA1A6B3Q35095351-D33DA97D-81CB-4434-A65A-9C9E8F4C36CAQ35611074-24F803A7-6F56-4971-811A-FCA291AE57A7Q35748383-8836D3D4-B45B-4E82-B56E-5B9C1FE06446Q36210972-2EC2E6A9-EAC7-434A-BB14-5AE9AEF03552Q36464788-64F12118-7F44-4A55-8616-BA42C5B0857DQ36573908-B0B5B0A8-6C80-4D54-ABEB-BBFF2A6BD4E9Q36618555-484B7875-FE25-495F-917C-3B05817A8640Q36965883-97FC0751-7F37-4299-A852-DE4F123D6A80Q37071183-FAF3C485-D90B-4460-A65C-871C7D25C611Q37193748-7ED6AE9C-7E38-49C4-9419-051DD5A2CADBQ37259401-2FC137C3-52CB-471F-8366-A6BEBA6E05D4Q38162928-F7D97D50-6030-466E-AF3A-B84586E6807EQ38260964-60246E8A-D12F-4530-B50F-23650DE103E3Q39455857-2F5EE4ED-E0D5-4486-92E5-1DFFB322636BQ40123629-B5263CC6-0C7E-411A-A65D-DC0815BDA3EFQ41940930-D0D3129A-2C63-4F95-89A0-7361DE7AC968Q42016883-909A6F9B-E658-4E27-A499-83D9F5951948Q42089817-97A361E1-C2E6-420A-8F4C-F49524982DFFQ42096203-DC152EFB-4CBE-4A67-AB4F-E821D6F1A4F5Q42165162-00F74B6B-17E6-4E02-90AC-532E5563340FQ45242050-E9838541-4EE2-4C94-B663-BC5D1CFAEA02
P2860
Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Insights into the biochemical ...... curring hypoglycemia mutations
@ast
Insights into the biochemical ...... curring hypoglycemia mutations
@en
Insights into the biochemical ...... curring hypoglycemia mutations
@en-gb
Insights into the biochemical ...... curring hypoglycemia mutations
@nl
type
label
Insights into the biochemical ...... curring hypoglycemia mutations
@ast
Insights into the biochemical ...... curring hypoglycemia mutations
@en
Insights into the biochemical ...... curring hypoglycemia mutations
@en-gb
Insights into the biochemical ...... curring hypoglycemia mutations
@nl
prefLabel
Insights into the biochemical ...... curring hypoglycemia mutations
@ast
Insights into the biochemical ...... curring hypoglycemia mutations
@en
Insights into the biochemical ...... curring hypoglycemia mutations
@en-gb
Insights into the biochemical ...... curring hypoglycemia mutations
@nl
P2093
P50
P921
P1433
P1476
Insights into the biochemical ...... curring hypoglycemia mutations
@en
P2093
Carol Buettger
Chyio Shiota
Franz M Matschinsky
Ian W Campbell
Michèl A A P Willemsen
Paula Midgley
Wayne W K Lam
P304
P356
10.2337/DIABETES.52.9.2433
P407
P577
2003-09-01T00:00:00Z